Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ganzini L, Casey DE, Hoffman WF, McCall AL (1993). The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 153: 1469–75.
Literatur
Johnson MD, Lavin P, Whetsell WO Jr (1990). Fulminant monophasic multiple sclerosis, Marburg’s type. J Neurol Neurosurg Psychiatry 53(10):918–921.
Keegan M, Pineda A, McClelland R (2002) Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58: 143–146.
Mendez MF, Pogacar S (1988). Malignant monophasic multiple sclerosis or „Marburg’s disease“. Neurology 38(7):1153–1155.
Poser S, Luer W, Bruhn H, Frahm J, Bruck Y, Felgenhauer K (1992). Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 86(6):579–585.
Rodriguez M, Karnes WE, Bartleson JD et al. (1993) Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 43:1100–1104.
Stoll G, Brück W (2001). Sonderformen der Multiplen Sklerose. In: Zettl UK, Mix E. (Hrsg.) Multiple Sklerose — Kausalorientierte, symptomatische und rehabilitative Therapie. Springer-Verlag, Berlin-New York 81–90.
Weinchenker BG (1999). Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. J Clin Apheresis 14: 144–148.
Zettl UK, Lehmitz R, Mix E (2003). Klinische Liquordiagnostik. De Gruyter, Berlin-New York 2003.
Literatur
Abele M, Burk K, Schols L et al. (2002) The aetiology of sporadic adult-onset ataxia. Brain 125: 961–968.
Harding AE (1981). „Idiopathic“ late onset cerebellar ataxia. A clinical and genetic study of 36 cases. J Neurol Sci 51: 259–271.
Literatur
Kimura J (1989) Electrodiagnosis in diseases of nerve and muscle: principles and practice. F.A. Davis Company, Philadelphia.
Literatur
Kortmann RD, Kuhl J, Timmermann B et al. (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT’ 91. Int J Radiat Oncol Biol Phys 15:269–79.
Bode U, Fleischhack G (1998). Tumoren des Nervensystems im Kindesalter. In: Schlegel U, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart New York. 342–375.
Chang CH, Housepian EM, Herbert C Jr. (1969). An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93:1351–9.
Literatur
Safa G, Joly P, Boullie MC, Thomine E, Lauret P (1995) Melkersson-Rosenthal syndrome treated by thalidomide. Two cases. Ann Dermatol Venereol 122: 609–611.
Stein SL, Mancini AJ (1999) Melkersson-Rosenthal syndrome in childhood: successful management with combination steroid and minocycline therapy. J Am Acad Dermatol 41:746–748.
Sussman GL, Yang WH, Steinberg S (1992) Melkersson-Rosenthal syndrome; clinical, pathologic, and therapeutic considerations. Ann Allergy 69: 187–194.
Literatur
Tsukada T, Yamaguchi K, Kameya T (2001). The MEN1 Gene and Associated Diseases: An Update. Endocr Pathol 12:259–273.
Kato H, Uchimura I, Morohoshi M et al. (1996) Multiple endocrine neoplasia type 1 associated with spinal ependymoma. Intern Med 35:285–9.
Literatur
Pareschi R et al. Posterior fossa vestibular neurotomy as primary surgical treatment of Meniere’s disease: a re-evaluation. J Laryngol Otol 2002; 116:593–596.
Welling DH et al. Endolymphatic mastoid shunt: a reevalutation of efficacy. Otolaryngol Head Surg 2000; 122:340–345.
Yetiser S et al. Intratympanic gentamicin in Meniere’s disease: the impact on tinnitus. Int J Audiol 2002; 41:363–70).
Literatur
Preston-Martin S (1990). Descriptive epidemiology of primary tumors of the spinal cord and spinal meninges in Los Angeles county, 1972–1985. Neuroepidemiol 9:106–111.
Literatur
Kondziolka D, Levy EI, Niranjan A et al. (1999) Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. J Neurosurg 91:44–50.
Debus J, Wuendrich M, Pirzkall A (2001). High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. J Clin Oncol 19:3547–53.
Schrell U, Rittig MH, Anders M et al. (1997) Hydroxyurea for treatment of unresectable and recurrent meningingiomas. J Neurosurg 86:840–44.
Literatur
Dexamethasone in Adults with Bacterial Meningitis. J. de Gans, D. van de Beek. NEJM 347:1549–1556, Nov 2002
Literatur
Kilburn P (1957) Meralgia paraesthetica. Lancet II: 952.
Literatur
Gorson KC, Ropper AH, Weinberg DH, Weinstein R (2002). Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 59(5):766–772.
Kelly JJ Jr, Adelman LS, Berkhman E, Bhan I (1988). Polyneuropathy associated with IgM monoclonal gammopathies. Arch Neurol 45:1355–1359.
Kyle RA, Dyck PJ (1993). Neuropathy associated with the monoclonal gammopathies. In: Dyck PJ, Thomas PK (Hrsg.) Peripheral Neuropathy. Saunders Philadelphia, Pennsylvania, 1275–1287.
Kyle RA, Dyck PJ (1993). Osteosclerotic myeloma (POEMS syndrome). In: Dyck PJ, Thomas PK (Hrsg.) Peripheral Neuropathy. Saunders Philadelphia, Pennsylvania, 1288–1293.
Leger JM, Younes-Chennoufi AB, Chassande B, et al. (1994). Human immunoglobulin treatment in multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry 57:46–49.
Nobile-Orazio E, Carpo M (2001). Neuropathy and monoclonal gammopathy. Curr Opin Neurol 14(5):615–620.
Literatur
Empfehlungen der Deutschen Migräne-und Kopfschmerzgesellschaft.
Tfelt-Hansen P, Henry P, Mulder LJ, Schaeldewaert RG, Schoenen J, Chazot G (1995) The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346: 923–926.
The Diclofenac-K/Sumatriptan Migraine Study Group (1999) Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia19(4): 232–40.
Literatur
Berlit P, Rakicky J (1992). The Miller Fisher syndrome. Review of the literature. J Clin Neuroophthalmol 12:57–63.
Gareth J, Parry MB (1993). Guillain-Barré syndrome. Thieme Medical Publishers, New York.
Fisher M (1956). An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 255:57–65.
Vedeler CA (2000). Inflammatory neuropathies: update. Curr Opin Neurol 13:305–309.
Willison HJ, Veitch J (1994). Immunoglobin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neuroimmunol 50:159–165.
Literatur
Bremner JD. A double-blind comparison of Org 3770, amitryptilin and placebo in major depression. J Clin Psych 1995; 56:519–525
Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled date. Int Clin Psychopharmacol 1995; 10Suppl.4:25–35
Moffaert von et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995; 10:3–9
Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol. 1995; 10Suppl 4:37–45.
Timmer CJ et al. Clinical pharmacokinetics of mirtazepine. Clin Pharmacokinet 2000; 38:461–74.
Literatur
Faulds D, Balfour JA, Chrisp P, Langtry HD (1991). Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutical potential in the chemotherapy of cancer. Drugs 41:400–449.
Hartung HP, Gonsette R, König N et al. (2002) The Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. The Lancet 360:2018–25.
Literatur
Gilon D, Buonanno FS, Joffe MM, Leavitt M, Marshall JE, Kistler JP, Levine RA (1999). Lack of evidence of an association between mitralvalve prolapse and stroke in young patients. N Engl J Med 341(1):8–13.
Literatur
Neundörfer B (1987) Polyneuritiden und Polyneuropathien. VCH Verlagsgesellschaft, Weinheim.
Literatur
Greenfield J, Rea J, Ilfeld F (1984) Morton’s interdigital neuroma. Indications for treatment by local injections versus surgery. Clin Orthop 185:142–144.
Literatur
Dyck PJ (1993) Neuronal atrophy and degeneration predominantly affecting peripheral sensory and autonomic neurons. In: Dyck PJ, Thomas PK (eds) Peripheral Neuropathy. W. B. Saunders Company, Philadelphia, London, pp 1065–1093.
Literatur
Chaudry V, Corse AM, Cornblath DR, et al. (1993). Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 33:237–242.
Gold R, Toyka KV (2001). Immuntherapie neurologischer Erkrankungen. Uni-Med, Bremen.
Elliott Jl, Pestronk A (1994). Progression of multifocal motor neuropathy during apparently successful treatment with immunglobulin. Neurology 44, 967–968.
Feldman EL, Bromberg MB, Albers JW, Pestronk A (1991). Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 30:397–410.
Meucci N, Cappellari A, Barbieri S, et al. (1997) Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 63:765–769.
Nobile-Orazio E (1996). Multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 60:599–603.
Nobile-Orazio E (2001). Multifocal motor neuropathy. J Neuroimmunol 115(1–2):4–18.
Pestronk A (1991). Motor neuropathies, motor neuron disorders, and antiglycolipid antibodies. Muscle & Nerve 14:927–936.
Pestronk A (1998). Multifocal motor neuropathy: diagnosis and treatment. Neurology 51, 22–24.
Literatur
IFNB Multiple Sclerosis Study Group (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 43:655–61.
Jacobs LD, Cookfair DL, Rudick RA et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–94.
PRISMS Study Group (1998). Randomised double-blind placebo-controlled study of interferon-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504.
IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group (1995). Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 45:1277–85.
European Study Group on interferon beta-1b in secondary progressive MS (1998). Placebo controlled multicentre randomised trial of interferon beta 1-b in the treatment of secondary progressive multiple sclerosis. Lancet 352:1491–7.
PRISMS-4 (2001). Long-term efficacy of interferon beta-1a in relapsing MS. Neurology 56:1628–36.
Jacobs LD, Beck RW, Simon JH et al and the CHAMPS Study Group (2000). Intramuscular interferon beta-1a therapy initiated during the first demyelinating event in multiple sclerosis. N Engl J Med 343:898–904.
Johnson KP, Brooks BR, Cohen JA et al. (1995) Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268–76.
SPECTRIMS Study Group, Secondary Progressive Efficacy Trial of Recombinant Interferon beta-1a in MS (2001). Randomised controlled trial of Interferon beta-1a in secondary progressive MS: clinical results. Neurology 56:1496–504.
Hartung HP, Gonsette R, König N et al. The Mitoxantrone in Multiple Sclerosis Study Group (MIMS) (2002). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, doubleblind, randomised, multicentre trial. Lancet 360:2018–25.
Wiendl H, Lehmann HC, Hohlfeld R, Hartung HP, Kieseier BC (2003) Immunmodulierende Therapiestrategien bei der multiplen Sklerose. Akt Neurol 30:433–441.
Literatur
Hoffmann F (2002). Symptomatische Therapie. In: Schmidt RM, Hoffmann F (Hrsg.) Multiple Sklerose. Urban & Fischer München-Jena. S. 182–236.
Netz J, Hömberg V (2001). Ergotherapie bei Multipler Sklerose. In: Zettl UK, Mix E. Multiple Sklerose. Kausalorientiert, symptomatische und rehabilitative Therapie. Springer-Verlag, Berlin New York, S. 317–323.
Petajan HJ, Grappmair E, White AT et al. (1996) Impact of aerobic training for fitness und quality life in multiple sclerosis. Ann Neurol 39:432–441.
Literatur
Keegan M, Pineda A, McClelland R (2002). Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58:143–146.
MS-Therapie Konsensus Gruppe (2002). Immunmodulatorische Stufentherapie der Multiplen Sklerose: Neue Aspekte und praktische Umsetzung, März 2002. Nervenarzt 73:556–563.
Oliveri R, Valentino P, Russo C et al. (1998) Randomized trial comparing two different high doses of methylprednisolone in MS. Neurology 50:1833–1836.
Weinshenker B, O’Brien P, Petterson T et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878–886.
Literatur
Achiron A, Ziv I, Djadetti R et al. (1992) Aphasia in multiple sclerosis: clinical and radiologic correlations. Neurology 42:2195–2197.
Hartelius I, Runmarker B Andersen O (2000). Prevalence and characteristics of dysarthria in a multiple sclerosis incidence cohort: relation to neurological data. Folia Phoniatr Logop 52:160–177.
Schönle PW (2001). Logopädie bei Multipler Sklerose. In: Zettl UK, Mix E. Multiple Sklerose. Kausalorientiert, symptomatische und rehabilitative Therapie. Springer-Verlag, Berlin New York. S. 317–323.
Literatur
Alusi SH, Worthington J, Glickmann S et al. (2001). A study of tremor in multiple sclerosis. Brain 124:720–730.
Dettmers C (2001). Wohnortnahe Rehabilitation bei Multipler Sklerose. In: Zettl UK, Mix E. Multiple Sklerose. Springer-Verlag, Berlin New York. S. 293–305.
Pöllmann W, Albrecht H, Wötzel C et al. (2001) Physiotherapie bei der Multiplen Sklerose. In: Zettl UK, Mix E. Multiple Sklerose. Springer-Verlag, Berlin New York. S. 293–305.
Solari A, Filippini G, Gasco P et al. (1999) Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 52:57–62.
Thompson AJ (2000). The effectiveness of neurological rehabilitation in multiple sclerosis. J Rehabil Res Devel 37:455–461.
Thompson AJ (2002). Progress in neurorehabilitation in multiple sclerosis. Curr Opin Neurol 15:267–270.
Wiles CM, Newcombe RG, Fuller KJ et al. (2001) Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 70:174–179.
Wötzel C, Wehner C, Pöllmann W et al. (2000) Therapie der Multiplen Sklerose. Ein interdisziplinäres Behandlungskonzept. 2. Aufl. Pflaum, München.
Literatur
McDonald W, Compston A, Edan G, Goodkin D, Hartung H, Lublin F (2001). Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127.
MS-Therapie Konsensus Gruppe (2002). Immunmodulatorische Stufentherapie der Multiplen Sklerose: Neue Aspekte und praktische Umsetzung, März 2002. Nervenarzt 73:556–563.
Literatur
Kaufman DI, Trobe JD, Eggenberger ER et al. (2000) Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis. Neurology 54:2039–2044.
MS-Therapie Konsensus Gruppe (2002). Immunmodulatorische Stufentherapie der Multiplen Sklerose: Neue Aspekte und praktische Umsetzung, März 2002. Nervenarzt 73:556–563
Sellebjerg F, Nielsen H, Frederiksen J et al. (1999) A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 52:1479–1484.
Literatur
Barkhof F, Filippi M, Miller D et al. (1997) Comparision of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059–2069.
McDonald W, Compston A, Edan G, Goodkin D, Hartung H, Lublin F (2001). Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127.
Poser CM, Paty DW, Scheinberg L et al. (1983) New diagostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231.
Thompson A, Montalban X, Barkhof F et al. (2000) Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 47: 831–835.
Tintore M, Rovira A, Martinez M et al. (2000) Isolated demyelinating syndromes: comparison of different MR imaging critieria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 21:702–706.
Literatur
Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. (1999) Consensus statement on the diagnosis of multiple system atrophy [see comments]. J Neurol Sci 163: 94–8.
Graham JG, Oppenheimer DR (1969). Orthostatic hypotension and nicot sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiat 32: 28–34.
Quinn N (1989). Multiple system atrophy-the nature of the beast. J Neurol Psychiat Suppl 52:78–89.
Wenning GK, Quinn NP (1994). Multisystematrophy. Ann Neurol 21: 120–126.
Wenning und Quinn 1994
Literatur
Gross et al. (1998) The treatment of severe hyponatremia. Kidney Int Suppl. 64: 6–11.
Literatur
Wagner et al. (1991) Ann. Nutr. Metab 35:297–302.
Literatur
Benecke R (1996). Myoklonus, myoklonische Syndrome und ihre assozierten Erkrankungen. In: Conrad B, Ceballos-Baumann AO (Hrsg.) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart 199–221.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
(2005). M. In: Berlit, P. (eds) Therapielexikon Neurologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26367-5_13
Download citation
DOI: https://doi.org/10.1007/3-540-26367-5_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-67137-4
Online ISBN: 978-3-540-26367-8
eBook Packages: Medicine (German Language)